南網科技(688265.SH):擬不超2000萬元參設甬欣康君
格隆匯12月22日丨南網科技(688265.SH)公佈,為更好地實施公司戰略規劃,配合公司在生物醫藥等領域的產業生態佈局,賦能產業資源和研發資源,增強產業協同的效應,實現公司規模與產業佈局的跨越式發展。公司擬與關聯方康君投資管理(北京)有限公司(簡稱“康君資本”)、北京欣元至康企業管理諮詢合夥企業(有限合夥)(簡稱“欣元至康”)及其他有限合夥人出資參與投資甬欣康君,成為有限合夥人之一。甬欣康君總募集規模上限暫為人民幣20億元,首期規模為人民幣9億元,公司擬以自有資金認繳出資不超過人民幣2,000萬元,出資比例約佔該基金首期規模的2.22%。公司對其他投資人不承擔保底收益、退出擔保等或有義務。
投資方向:主要針對 1) 生物醫藥及生命健康領域有實力的創新型技術、平台和服務類企業的相關未上市企業和非上市公眾企業; 2)
生物醫藥領域具有併購能力的行業龍頭企業和併購整合型交易機會,進行股權投資或以股權投資為目的的非公開發行或者交易的可轉債、可交換債投資、市場化和法治化債轉股投資以及中國證監會認可的其他投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.